Clinical trials: Neuromuscular Blockade Reversal Agent, open to volunteers
Neuromuscular Blocking Agents, Residual Neuromuscular Block
Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Sevoflurane Anesthesia
Safety during modern practice of anaesthesia is of great concern. Patients admitted daily for surgical procedures undergoing general anaesthesia for different types of operations are exposed to different risks, starting from the…
- Conditions
- Neuromuscular Blocking Agents, Residual Neuromuscular Block, Reversal of Neuromuscular Blockade
- Trial name
- RPINMBWS (NCT07044193)
- Testing
- pipecuronium bromide, Rocuronium bromide
- Where
- Hungary
- Volunteers
- 80 people
- Sponsor
- Tamas Vegh, MD
Curarization, Postoperative Residual
A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 and 24 Months Old
Sugammadex is a drug used more and more frequently in infants as a rocuronium' s reversal agent. It has multiples benefits over other reversal agents such as a rapid onset of action and a complete reversal no matter how deep is…
- Trial name
- SUGAPEDIA (NCT07477132)
- Testing
- Sugammadex
- Where
- France
- Volunteers
- 99 people
- Sponsor
- University Hospital, Caen
Reversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery, Reversing Rocuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery
A Dose-Finding Study of Amogammadex Sodium for Reversing Vecuronium and Rocuronium-Induced Neuromuscular Blockade
Background context: Amogammadex sodium has completed Phase I-III clinical studies in China for reversal of rocuronium-induced blockade. No clinical studies have yet been conducted for vecuronium-induced blockade.
- Trial name
- NCT07595393
- Testing
- Rocuronium (0.6mg/kg), vecuronium bromide (0.1mg/kg)
- Volunteers
- 64 people
- Sponsor
- Amckaus PTY LTD.
Neuromuscular Blockade Reversal Agent, Perioperative Complications
Sugammadex-Induced Clenching During Neuromuscular Blockade Reversal
Study Objective: This study aims to evaluate the incidence, severity, and risk factors of sugammadex-induced mouth clenching during neuromuscular blockade (NMB) reversal in adult surgical patients.
- Conditions
- Neuromuscular Blockade Reversal Agent, Perioperative Complications, Anesthesia, General, Sugammadex
- Trial name
- NCT06962007
- Testing
- Sugammadex 1 mg/kg Group, Sugammadex 2 mg/kg Group, Sugammadex 4 mg/kg Group
- Where
- South Korea
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Wonkwang University Hospital